Claims for Patent: 10,704,038

Summary for Patent: 10,704,038

Title:	Therapeutic fusion proteins
Abstract:	The present invention relates to the construction of a new class of Targeted Secretion Inhibitors (TSIs), which comprise a non-cytotoxic protease, translocation peptide and a targeting moiety peptide, wherein the targeting moiety peptide has a free N-terminal domain and a free C-terminal domain; to a single-chain fusion protein precursor thereof, and to a method of activating said single-chain fusion protein precursor.
Inventor(s):	Chaddock; John (Abingdon, GB), Harper; Elaine (Abingdon, GB)
Assignee:	IPSEN BIOINNOVATION LIMTIED (Abingdon, GB)
Application Number:	16/105,203
Patent Claims:	1. A nucleic acid encoding a single-chain polypeptide fusion protein comprising: (a) a non-cytotoxic protease capable of cleaving a protein of the exocytic fusion apparatus of a target cell; (b) a targeting moiety capable of binding to a binding site on the target cell, which binding site is capable of undergoing endocytosis and being incorporated into an endosome within the target cell; (c) a translocation domain capable of translocating the protease from within an endosome, across the endosomal membrane, and into the cytosol of the target cell; (d) a first cleavage site that is cleavable by a protease, wherein the first cleavage site is located between the non-cytotoxic protease and the translocation domain; and (e) a second cleavage site that is cleavable by a protease, wherein the second cleavage site is located between the translocation domain and the targeting moiety and is not a destructive cleavage site; wherein the targeting moiety and the translocation domain are capable of forming a covalent linkage such that, following proteolytic cleavage at the second cleavage site, the targeting moiety remains linked to the translocation domain by the covalent linkage. 2. The nucleic acid of claim 1, wherein the translocation domain of the fusion protein is located between the non-cytotoxic protease and the targeting moiety. 3. The nucleic acid of claim 1, wherein the non-cytotoxic protease of the fusion protein is located at the N-terminus of the protein. 4. The nucleic acid of claim 1, wherein the covalent linkage of the fusion protein is a disulfide linkage. 5. The nucleic acid of claim 1, wherein a short polypeptide that provides a secondary polypeptide structure is located between the translocation domain of the fusion protein and the targeting moiety, and wherein the secondary polypeptide structure acts to bring part of the targeting moiety into close proximity to the translocation domain, thereby making formation of the covalent linkage energetically more favorable. 6. The nucleic acid of claim 1, wherein the targeting moiety of the fusion protein comprises first and second domains, and wherein the first and second domains are separated by at most 10 amino acid residues. 7. The nucleic acid of claim 6, wherein the first and second domains of the targeting moiety are derived from ligands to different receptors. 8. The nucleic acid of claim 1, wherein, following cleavage of the fusion protein at the first and second cleavage sites, the targeting moiety of the fusion protein is capable of interacting with the binding site on the target cell (i) via an interaction between an N-terminal domain of the targeting moiety and a domain of the binding site, and, simultaneously, (ii) via an interaction between a C-terminal domain of the targeting moiety and a domain of the binding site. 9. The nucleic acid of claim 1, wherein the targeting moiety of the fusion protein comprises a peptide selected from the group consisting of: a gonadotropin-releasing hormone (GnRH) peptide, an opioid peptide, a beta-endorphin peptide, a bradykinin peptide, a BAM peptide, a nociceptin peptide, a dynorphin peptide, a galanin peptide, an enkephalin peptide, a substance P peptide, a corticotropin-releasing factor (CRF) peptide, a gastrin-releasing peptide (GRP), a Neuromedin B peptide, a bombesin peptide, a gastrin peptide, a CCK peptide, a somatostatin (SST) peptide, a cortistatin (CST) peptide, a growth hormone releasing hormone (GHRH) peptide, a PAR peptide, a parathyroid hormone (PTH) peptide, a vasointestinal peptide (VIP), a beta2 adrenoreceptor agonist peptide, a gastrin-releasing peptide, a calcitonin gene related peptide, a thyroid stimulating hormone (TSH) peptide, an insulin peptide, an insulin-like growth factor peptide, a gonadorelin peptide, a corticotrophin releasing hormone (CRH) peptide, an adrenocorticotropic hormone (ACTH) peptide, and a pituitary adenyl cyclase activating peptide (PACAP). 10. The nucleic acid of claim 1, wherein the non-cytotoxic protease of the fusion protein and the first cleavage site are separated by at most 10 amino acid residues. 11. The nucleic acid of claim 1, wherein the translocation domain of the fusion protein and the first cleavage site are separated by at most 10 amino acid residues. 12. The nucleic acid of claim 1, wherein the translocation domain of the fusion protein and the second cleavage site are separated by at most 10 amino acid residues. 13. The nucleic acid of claim 1, wherein the targeting moiety of the fusion protein and the second cleavage site are separated by at most 10 amino acid residues. 14. The nucleic acid of claim 1, wherein the first and second cleavage sites are capable of being cleaved by the same protease. 15. The nucleic acid of claim 1, wherein the non-cytotoxic protease of the fusion protein is a clostridial neurotoxin L-chain or a fragment thereof. 16. The nucleic acid of claim 1, wherein the translocation domain of the fusion protein is a clostridial neurotoxin H.sub.N domain or a fragment thereof. 17. The nucleic acid of claim 1, wherein the fusion protein encoded by the nucleic acid comprises a purification tag. 18. A DNA vector comprising a promoter, the nucleic acid sequence of claim 1, and a terminator, wherein the nucleic acid sequence is located downstream of the promoter and the terminator is located downstream of the nucleic acid sequence. 19. The complementary DNA strand of the nucleic acid of claim 1.

Details for Patent 10,704,038

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2031-05-16